If the Myriad myChoice® CDx is used for tumour HRD testing, our data support a testing model of germline and tumour BRCA1/2 testing in all patients diagnosed with epithelial ovarian cancer aged < 79 years old, with germline BRCA1/2 testing only necessary for patients aged ≥ 80 years old with a tumour BRCA1/2 pathogenic variant. This evidence concerns the gene BRCA1 and neoplasm.